D-0093-2022 Class I Terminated

Recalled by MERCK SHARP & DOHME CORP — Whitehouse Station, NJ

Recall Details

Product Type
Drugs
Report Date
November 10, 2021
Initiation Date
October 19, 2021
Termination Date
July 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
76,163 vials

Product Description

Cubicin (daptomycin for injection), 500 mg per vial, Single-dose vial, Rx only. Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Manuf. by: Baxter Pharmaceuticals LLC., Bloomington, IN 47403, USA, NDC: 67919-011-01

Reason for Recall

Presence of Particulate Matter: Identified as Glass Particles

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: 934778, Exp. Date Jun 2022